MAGLE CHEMOSWED HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.4 SEK | +1.25% |
|
+1.25% | +28.57% |
| 18/04 | Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 22/03 | Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +28.57% | 3.19Cr | - | ||
| +29.98% | 68TCr | C+ | ||
| +30.34% | 57TCr | B | ||
| -3.52% | 36TCr | C+ | ||
| +18.59% | 33TCr | B- | ||
| +4.07% | 28TCr | C+ | ||
| +16.21% | 24TCr | B+ | ||
| +9.66% | 21TCr | B- | ||
| -6.83% | 20TCr | A+ | ||
| +7.09% | 17TCr | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
- Stock Market
- Equities
- MAGLE Stock
- Ratings Magle Chemoswed Holding AB